• News Archive
  • Simaster
  • Webmail
  • Directory
  • Crisis Center
  •  English
    • Indonesia
Universitas Gadjah Mada Universitas Gadjah Mada Universitas Gadjah Mada Universitas Gadjah Mada
  • Education
    • Doctoral dissertation
    • Inauguration of Professor
    • Graduation
  • Achievement
  • Research and Innovation
    • Research
    • Innovation
  • Campus Info
    • Cooperation
    • Seminar and Workshop
    • Student Community Service Program
    • Other
  • News Report
  • Home
  • Faculty Corner
  • Upholding Vaccine Development, UGM FKKMK Publishes SARS-Cov-2 Genome Sequencing

Upholding Vaccine Development, UGM FKKMK Publishes SARS-Cov-2 Genome Sequencing

  • 28 August 2020, 09:41 WIB
  • By: Natasa Adelayanti
  • 837
Dukung Pengembangan Vaksin, FKKMK UGM Publikasikan Sequencing Genom SARS-Cov-2

UGM Faculty of Medicine, Public Health, and Nursing continues efforts to handle the Covid-19 Pandemic in Indonesia through several research and innovation activities. One of the discoveries for the success of research and innovation achieved in August 2020 was the UGM FKKMK Genetic Working Group advising 4 SARS-Cov-2 genome sequencing with high-grade coverage quality from 4 COVID-19 patients.

"The concern is not only for research but also for the development of global vaccines or especially red and white vaccines because one of the significant factors in vaccine production is the type of mutation or clade," said the Head of the Genetics Working Group (Pokja), dr. Gunadi, SpBA., PhD., on Thursday (27/8).

Of the 4 SARS-Cov-2 genome sequences, 3 data were successfully published in the global database of 'GISAID' coronavirus genome sequencing on Tuesday (24/08). The 3 SARS-Cov-2 isolates were named hCoV-19 / Indonesia / YO-202449/2020, hCoV19 / Indonesia / YO-200927/2020, and hCoV-19 / Indonesia / YO-781481/2020.

Gunadi further said that the publication of genome sequencing at GISAID has probably been important information for scientists worldwide to understand the coronavirus, including its mutations, and support vaccine development efforts.

"From these results, we can contribute to the development of a vaccine or coronavirus therapy in the future," he said.

Based on this achievement, Universitas Gadjah Mada joined teams with LBM Eijkman, Airlangga University, and West Java, which had earlier published its genome sequencing on GISAID. GISAID is an international data bank with collaborative data from scientists around the world and provides genetic/genomic, clinical, and epidemiological data related to flu viruses, including SARS-Cov-2.

Genetic Working Group of UGM FKKMK in the process of identifying the sequencing of the SARS-Cov-2 genome have partnership with the Wates Veterinary Center, Kulon Progo, DIY, the Indonesian Ministry of Agriculture, the UGM FKKMK COVID-19 Diagnostic Laboratory (Department of Microbiology and Diagnostic Laboratory of the Tahija World Mosquito Program Foundation / WMP Yogyakarta Center for Tropical Medicine), Integrated Research Laboratory FKKMK UGM, Department of Computer Science and Electronics, FMIPA UGM and COVID-19 referral hospital.

Besides Gunadi, there are also some researchers involved namely drh. Hendra Wibawa, PhD. dr. Marcellus, dr. Mohamad S. Hakim, PhD, dr. Edwin W. Daniwijaya, PhD, dr. Ludhang P. Rizki, MSc, SpMK, Endah Supriyati, MSc, dr. Eggi Arguni, SpAK, PhD, dr. Titik Nuryastuti, PhD, SpMK (K), Prof. dr. Tri Wibawa, PhD, SpMK (K), dr. Dwi AA Nugrahaningsih, MSc, PhD, Afiahayati, PhD, dr. Siswanto, SpP, dr. Beby Dewi Sartika, SpPD, dr. Ardorisye Saptaty Fornia, SpP, dr. Alvin S. Kalim, dr. Desyifa Mursalin, dr. Dyah Ayu Puspitarani, dr. Kemala Athollah, and dr. Dwiki Afandy.

Gunadi revealed that the samples published on GISAID came from the first batch research. Currently, the team is preparing the SARS-Cov-2 genome running sequencing for the next batch.

"By taking lessons from our experience in the first batch, hopefully, the next batch will be successful in identifying the SARS-Cov-2 genome sequencing is more notable," he concluded.


Author: Gloria
Translator: Natasa A

 

Related News

  • UGM Expert: Clinical Trials, the Way to Prove Covid-19 Vaccines Effectiveness in Indonesia

    Thursday,23 July 2020 - 13:21
  • Mutation of D614G SARS-CoV2 Virus with Potential of Higher Infection Detected in Yogyakarta and Central Java

    Tuesday,01 September 2020 - 13:55
  • Virology Expert: Vaccine is Not One and Only Solution to Stop Covid-19

    Tuesday,18 August 2020 - 10:41
  • Challenge in Vaccine Progress: Coronavirus Continues to Mutate

    Friday,22 May 2020 - 16:38
  • UGM Discovers 4 Mutations of Coronavirus in Yogyakarta and Central Java

    Wednesday,02 September 2020 - 17:20

News Releases

  • 18,964 UGM Students Receive Scholarships, Director of Student Affairs Says 20 January 2023
    Universitas Gadjah Mada (UGM) annually allocates hundreds
    Salma
  • Prof. Budi Setiadi Daryono Recounts Origin of His Apple Melon Cultivar 'Hikapel' 16 January 2023
    In 2012, a team of researchers from the UGM Facult
    Salma
  • UGM Graduate Fajar Kelana Named Top 20 International James Dyson Award Winner 13 January 2023
    Fajar Sidik Abdullah Kelana, an alumnus of UGM and
    Salma
  • Chemical Eng. Students Win International Youth Ideas Competition 05 January 2023
    UGM Chemical Engineering students Andhirta Rukmarata Chani
    Salma
  • UGM Secures IDR 67 Billion From 2022 Kedaireka Matching Fund, Most Among Other Universities 30 December 2022
    Universitas Gadjah Mada (UGM) has topped the list of unive
    Salma

Event

No latest event at this time

Universitas Gadjah Mada
UNIVERSITAS GADJAH MADA
Bulaksumur Yogyakarta 55281
   info@ugm.ac.id
   +62 (274) 588688
   +62 (274) 565223
   +62 811 2869 988

PARTNERSHIP

  • Alumni
  • International Affairs

ABOUT UGM

  • Rector's Welcome
  • History
  • Vission and Mission
  • The Board of Executive
  • Management

VISIT UGM

  • Campus Map
  • Event

REGISTRATION

  • Undergraduate
  • Graduate
  • Vocational School
  • Professional Program
  • International Program

© 2023 Universitas Gadjah Mada

PRIVACY POLICYCONTACT